Registrering slutförd!
Användarkonto uppsatt – validering hanteras.
Ditt användarkonto har upprättats, men vi behöver validera att du är Hälso-och sjukvårdspersonal. Vi skickar dig ett e-postmeddelande inom några dagar när validering är gjord.
Under tiden kan du besöka den öppna delen av GSKs hemsida.
March 2018
CROI 2018—Safety and efficacy of dolutegravir-based ART and efavirenz-based ART in TB/HIV co-infected adults at Week 24 1
Effectiveness of dolutegravir or efavirenz in combination with 2 NRTIs in HIV/TB co-infected adults receiving rifampin-based TB therapy
Authors: Dooley KE, Kaplan R, Mwelase T, et al
- Ongoing Phase IIIb, non-comparative, active-control, randomised open-label study
- DTG 50 mg twice daily shown to be effective and well tolerated in ART-naïve HIV/TB co-infected adults receiving RIF-based TB therapy
- Of 113 subjects, 69 were randomised to DTG and 44 to EFV
- Week 24: HIV-1 RNA <50 c/mL was 81% (n=56) in the DTG arm and 89% (n=39) in EFV arm
- DTG response rate driven by non–treatment-related Snapshot failures:
- 5 participants (7%) in the DTG arm and 0 in the EFV arm discontinued due to non–treatment-related reasons
- No subjects discontinued due to immune reconstitution inflammatory syndrome (IRIS) or liver events, while TB-associated rates of IRIS were low (DTG, n=4 [6%]; EFV, n=4 [9%])
Access the full abstract here.
“…DTG 50 mg twice daily shown to be effective and well tolerated in HIV/TB co-infected adults receiving RIF-based TB therapy.”
